GLOBAL RESEARCH, DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AND LICENSE AGREEMENTGlobal Research, Development and Commercialization Collaboration and License Agreement • May 7th, 2014 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This Global Research, Development and Commercialization Collaboration and License Agreement (this “Agreement”), is entered into as of January 8, 2014 (the “Execution Date”), by and between Sangamo BioSciences, Inc., a company organized under the laws of Delaware and having a place of business at 501 Canal Blvd., Suite A100, Richmond, CA 94804 (“Sangamo”), and Biogen Idec Ma Inc., a Massachusetts corporation having a place of business at 14 Cambridge Center, Cambridge, MA 02142 (“Biogen Idec”, and each of Biogen Idec and Sangamo, a “Party” or collectively the “Parties”).
NINTH AMENDMENTSangamo License Agreement • May 7th, 2014 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Ninth Amendment, effective as of the date set forth above the signatures of the parties below, amends the Sangamo License Agreement dated May 9, 1996 (“SANGAMO LICENSE AGREEMENT”) between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA and Sangamo Biosciences Inc. (“COMPANY”), a corporation having its principal office at 501 Canal Blvd., Suite A100, Richmond, Ca 94804
